series-b
Stage
2
Investors
About
Invirsa develops INV-102, a drug compound that enhances the body's response to DNA damage to treat ocular conditions such as sulfur mustard gas injury and diabetic dry eye disease.
Explore Invirsa's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.